Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment
Laia Lorenzo-Esteller, Raúl Ramos-Polo, Alexandra Pons Riverola, Herminio Morillas, Javier Berdejo, Sònia Pernas, Helena Pomares, L. Asiáin, Alberto Garay, E. Martínez Pérez, Santiago Jiménez‐Marrero, L Alcoberro, Ernest Nadal, Paula Gubern-Prieto, Francisco Gual‐Capllonch, Encarna Hidalgo, Cristina Enjuanes, Josep Comín‐Colet, Pedro Moliner
Abstract
Pericardial disease is increasingly recognized in cancer patients, including acute pericarditis, pericardial effusion, and constrictive pericarditis, often indicating a poor prognosis. Acute pericarditis arises from direct tumor involvement, cancer therapies, and radiotherapy. Immune checkpoint inhibitor (ICI)-related pericarditis, though rare, entails significant mortality risk. Treatment includes NSAIDs, colchicine, and corticosteroids or anti-IL1 drugs in refractory cases. Pericardial effusion is the most frequent manifestation, primarily caused by lung cancer, followed by breast cancer, lymphoma, leukemia, gastrointestinal tumors, and melanoma. Chemotherapy, immunotherapy, and radiotherapy may also cause fluid accumulation in the pericardial space. Symptomatic relief for pericardial effusion may require pericardiocentesis, prolonged catheter drainage, or a pericardial window. Instillation of intrapericardial cytostatic agents may reduce recurrence. Constrictive pericarditis, though less common, often develops from radiotherapy and requires multimodality imaging for diagnosis, with pericardiectomy as the definitive treatment. Primary pericardial tumors are rare, with metastases being more frequent. Patients with cancer and pericardial disease generally have poor survival, emphasizing the need for early detection. A multidisciplinary approach involving hematologists, oncologists, and cardiologists is crucial to tailoring pericardial disease treatment to a patient's clinical status, thereby improving the quality of life and prognosis.